Scarica l'app Stockscreener
1.05
0.94%
-0.01
Dopo l'orario di chiusura:
1.05
Precedente Chiudi:
$1.06
Aprire:
$1.05
Volume 24 ore:
61,585
Relative Volume:
0.30
Capitalizzazione di mercato:
$34.40M
Reddito:
-
Utile/perdita netta:
$-60.70M
Rapporto P/E:
-0.5147
EPS:
-2.04
Flusso di cassa netto:
$-61.05M
1 W Prestazione:
-2.78%
1M Prestazione:
-0.94%
6M Prestazione:
-23.91%
1 anno Prestazione:
-50.70%
Intervallo 1D:
$1.05
$1.07
Intervallo di 1 settimana:
$1.05
$1.105
Portata 52W:
$0.87
$3.07
An 2 Therapeutics Inc Stock (ANTX) Company Profile
Nome
An 2 Therapeutics Inc
Settore
Industria
Telefono
(650) 331-9090
Indirizzo
1800 EL CAMINO REAL, SUITE D, MENLO PARK
Confronta ANTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
1.05 | 34.40M | 0 | -60.70M | -61.05M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-09 | Downgrade | Evercore ISI | In-line → Underperform |
| 2024-08-09 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-07-03 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-04-02 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2024-02-13 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-12 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-02-12 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-01-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
Mostra tutto
An 2 Therapeutics Inc Borsa (ANTX) Ultime notizie
$452M Deal: Processa's Phase 2 Gastroparesis Drug Shows Promise, Attracts Major Licensing Interest - Stock Titan
Layoff Tracker: ADC Therapeutics Cutting 30% of Staff, Closing London Research Facility - BioSpace
Celldex Presents Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci Congress 2025 - marketscreener.com
Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Intensity Therapeutics, Inc. Announces Pricing of Public Offering - PR Newswire
Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock - PR Newswire
Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study - Morningstar
Aclaris Therapeutics, Inc. Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - marketscreener.com
Lyra Therapeutics Reports Positive Results From The Enlighten 2 Phase 3 Trial Of Lyr-210 - marketscreener.com
Allarity Therapeutics Announces First Patient Enrolled in - GlobeNewswire
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer - The Manila Times
Sapience Therapeutics Provides Data Update from Phase 2 Trial of Lucicebtide in Patients with Glioblastoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - PR Newswire
Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - GlobeNewswire
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - GlobeNewswire
Certain Stock Options of Edgewise Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-JUN-2025. - marketscreener.com
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology - The Malaysian Reserve
Kymera Therapeutics, Inc. (KYMR) to Announce KT-621 Phase 1 Results on June 2, 2025 - Insider Monkey
Xilio Therapeutics Announces Updated Phase 2 Data for - GlobeNewswire
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - Yahoo Finance
Spero Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Transposon Announces TPN-101 Selected for Inclusion in the Phase 2/3 HEALEY ALS Platform Trial, Building on the Success of Phase 2 Study in C9orf72-related ALS - PR Newswire
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis - Business Wire
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PR Newswire
Type 2 Diabetes Market to Expand Significantly by 2034, States DelveInsight Report | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - The Globe and Mail
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025 - Yahoo Finance
Tango Therapeutics, Inc. Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients with MTAP-Deleted Glioblastoma and Other Solid Tumors - marketscreener.com
Tango Therapeutics Announces First Patient Dosed in TNG456 - GlobeNewswire
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors - Yahoo Finance
Viking Therapeutics: A High Potential Biotech Play With Manageable Risks (NASDAQ:VKTX) - Seeking Alpha
Verve Therapeutics Leads The Charge With 2 Other Promising Penny Stocks - simplywall.st
Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment - Yahoo Finance
Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 Data - Business Wire
Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen - Yahoo Finance
Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update - Business Wire
Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PR Newswire
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results - GlobeNewswire
Cognition Therapeutics Reports Topline Results Showing Oral - GlobeNewswire
Cognition Therapeutics, Inc. (CGTX) Reports Topline Results Showing Oral CT1812 Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - StreetInsider
Aligos Therapeutics, Inc. SEC 10-Q Report - TradingView
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer - GlobeNewswire
Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? - Yahoo Finance
PTC Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
PTC Therapeutics, Inc. Announces Results from the Phase 2 PIVOT-HD Study of PTC518 in Stage 2 and Stage 3 Huntington's Disease Patients - marketscreener.com
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF - The Victoria Advocate
TransCode Therapeutics (RNAZ) Adjourns Special Meeting to May 2 - GuruFocus
United Therapeutics Corporation Reports First Quarter 2025 Financial Results - Business Wire
Relmada Therapeutics, Inc. Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - marketscreener.com
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - Quantisnow
Protara Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Protara Therapeutics Shares Positive Phase 2 Interim Results Of TARA-002 In Patients With NMIBC - Nasdaq
Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering - PR Newswire
An 2 Therapeutics Inc Azioni (ANTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
An 2 Therapeutics Inc Azioni (ANTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Easom Eric | Chief Executive Officer |
Jun 02 '25 |
Buy |
1.07 |
10,000 |
10,665 |
256,380 |
| Leonard Braden Michael | 10% Owner |
May 28 '25 |
Sale |
1.16 |
2,100,000 |
2,436,000 |
3,649,432 |
| Leonard Braden Michael | 10% Owner |
May 30 '25 |
Sale |
1.01 |
432,000 |
436,477 |
3,217,432 |
| FitzPatrick Margaret M | Director |
May 28 '25 |
Buy |
1.18 |
8,610 |
10,133 |
8,610 |
| Day Lucy | Chief Financial Officer |
Jan 03 '25 |
Sale |
1.34 |
2,957 |
3,965 |
32,670 |
| Chanda Sanjay | Chief Development Officer |
Jan 03 '25 |
Sale |
1.34 |
2,957 |
3,965 |
29,824 |
| Prior Stephen David | Chief Strategy Officer |
Jan 03 '25 |
Sale |
1.34 |
2,029 |
2,721 |
33,313 |
| Eizen Joshua M | See Remarks |
Jan 03 '25 |
Sale |
1.34 |
9,663 |
12,958 |
116,672 |
| Readnour Robin Shane | Director |
Dec 09 '24 |
Buy |
1.43 |
30,772 |
43,984 |
647,573 |
| Readnour Robin Shane | Director |
Dec 06 '24 |
Buy |
1.45 |
19,228 |
27,795 |
629,090 |
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):